SEC Form 4Coverage since May 26, 2026
$OCUL insider trading
Over the last 12 months, Ocular Therapeutix insiders reported no purchases and 5 sales totaling $360K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $360K 5 events
- Events · 12m
- 5 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $OCUL · 12Mvia TradingView
Top insiders · 12m
Nayak SanjayChief Strategy Officer1× · $15K
Kaiser PeterChief Development Officer1× · $24K
Heier Jeffrey S.Chief Scientific Officer1× · $25K
Waheed NadiaChief Medical Officer1× · $123K
Dugel PravinSee Remarks1× · $173K
All insider trades
5 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Waheed NadiaChief Medical Officer · O | ▼ Sale | 14,828 | $8.27 | $123K | -4.7% | plan |
| May 26, 2026 | Dugel PravinSee Remarks · O·D | ▼ Sale | 21,156 | $8.2 | $173K | -0.8% | plan |
| May 26, 2026 | Kaiser PeterChief Development Officer · O | ▼ Sale | 2,967 | $8.2 | $24K | -1.1% | plan |
| May 26, 2026 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 3,018 | $8.2 | $25K | -0.9% | plan |
| May 26, 2026 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 1,858 | $8.2 | $15K | -0.6% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $OCUL feed.